Technical Analysis for AGEN - Agenus Inc.

Grade Last Price % Change $ Change
grade D $4.54 0.67% 0.03
AGEN closed up 0.67 percent on Tuesday, February 21, 2017, on 1.3 times normal volume.

Earnings due: Mar 1

Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical AGEN trend table...

Date Alert Name Type % Chg
Feb 21 Spinning Top Other 0.00%
Feb 21 Calm After Storm Range Contraction 0.00%
Feb 17 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.67%
Feb 17 180 Bullish Setup Bullish Swing Setup 0.67%
Feb 14 Volume Surge Other 3.18%
Feb 14 Wide Range Bar Range Expansion 3.18%
Feb 14 Gilligan's Island Sell Setup Bearish Swing Setup 3.18%
Feb 13 Crossed Above 50 DMA Bullish 10.19%
Feb 10 50 DMA Resistance Bearish 11.00%
Feb 9 50 DMA Resistance Bearish 12.38%

Older signals for AGEN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.

Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies. The company offers Oncophage vaccine for the treatment of renal cell carcinoma in patients at intermediate risk of recurrence. Its products under development include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of malaria, melanoma, non-small cell lung cancer, and shingles, as well as for the treatment of various infectious diseases, multiple cancer types, and Alzheimer’s disease; and HerpV, a therapeutic vaccine candidate that is in Phase 2 clinical trial for the treatment of genital herpes. The company’s products under development also comprise Prophage series of cancer vaccines, including R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its Prophage series of cancer vaccines were tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and are in Phase I and Phase II clinical trials for various indications, and in Phase II clinical trials for the treatment of diagnosed and recurrent glioma. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Is AGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 7.49
52 Week Low 2.7
Average Volume 1,111,244
200-Day Moving Average 4.89
50-Day Moving Average 4.13
20-Day Moving Average 4.06
10-Day Moving Average 4.24
Average True Range 0.24
ADX 24.67
+DI 30.03
-DI: 16.1
Chandelier Exit (Long, 3 ATRs) 4.06
Chandelier Exit (Short, 3 ATRs) 4.31
Upper Bollinger Band 4.57
Lower Bollinger Band 3.55
Percent B (%b) 0.97
Bandwidth 0.251232